| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 4.677 | 0 | 0 | 0 |
| Total Income - EUR | 23 | 0 | 0 | 111 | 0 | 0 | 4.677 | 203 | 0 | 0 |
| Total Expenses - EUR | 155 | 214 | 40 | 779 | 0 | 269 | 121 | 6 | 124 | 118 |
| Gross Profit/Loss - EUR | -132 | -214 | -40 | -668 | 0 | -269 | 4.555 | 197 | -124 | -118 |
| Net Profit/Loss - EUR | -132 | -214 | -40 | -672 | 0 | -269 | 4.418 | 191 | -124 | -118 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Pure Pharmaceuticals Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 8.280 | 8.063 | 7.909 | 7.095 | 6.958 | 6.557 | 10.967 | 10.880 | 10.723 | 10.544 |
| Inventories | 0 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 798 | 790 | 776 | 0 | 0 | 0 | 4.677 | 4.691 | 4.677 | 4.651 |
| Cash | 7.482 | 7.255 | 7.132 | 7.095 | 6.958 | 6.557 | 6.290 | 6.188 | 6.045 | 5.893 |
| Shareholders Funds | -3.593 | -3.771 | -3.747 | -4.350 | -4.265 | -4.453 | 63 | 133 | 8 | -110 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 11.872 | 11.834 | 11.655 | 11.445 | 11.223 | 11.010 | 10.904 | 10.747 | 10.714 | 10.654 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "2120 - 2120" | |||||||||
| CAEN Financial Year |
2120
|
|||||||||
Comments - Pure Pharmaceuticals Srl